Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.44 |
| ▸ | METAP2 | P50579 | 5/20 | 0.38 |
| ▸ | METAP1 | P53582 | 4/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275926 | 0.81 | REN (0.47) | RENMETAP2METAP1 | |
| SCHEMBL7275933 | 0.81 | REN (0.47) | RENMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL7437801 | 0.80 | REN (0.46) | RENMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL7442290 | 0.80 | REN (0.46) | RENMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL10775594 | 0.80 | REN (0.44) | RENMETAP2METAP1ALOX5CTSK | |
| Hydrochloric Acid SCHEMBL10775598 | 0.80 | REN (0.44) | RENMETAP2METAP1ALOX5CTSK | |
| SCHEMBL7279876 | 0.80 | REN (0.55) | RENMETAP2METAP1 | |
| SCHEMBL7277378 | 0.77 | REN (0.47) | RENMETAP2METAP1 | |
| SCHEMBL8682444 | 0.76 | REN (0.55) | RENMETAP2METAP1 | |
| SCHEMBL8682141 | 0.76 | REN (0.55) | RENMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | REN 662/4885METAP2 214/4885METAP1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.